docetaxel 50mg/m2

DRUG2 trials

Sponsors

Peng Wang, MD PhD, Instituto do Cancer do Estado de São Paulo

Conditions

Metastatic Hormone-Sensitive Prostate CancerProstate Cancer (Adenocarcinoma)

Phase 1

Toxicity & Pharmacokinetics of 2 & 3-weekly Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

WithdrawnNCT03343977

Peng Wang, MD PhDMetastatic Hormone-Sensitive Prostate Cancer

Start: 2018-02-14End: 2029-04-30Updated: 2018-07-17

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

Not yet recruitingNCT07316686

Instituto do Cancer do Estado de São PauloProstate Cancer (Adenocarcinoma)

Start: 2026-01-31End: 2026-12-31Target: 18Updated: 2026-01-05